Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors | Zendy

Matthew R. Weir | Zendy; George L. Bakris | Zendy; David A. Bushinsky | Zendy; Martha Mayo | Zendy; Dahlia Garza | Zendy; Yuri Stasiv | Zendy; Janet Wittes | Zendy; Heidi ChristSchmidt | Zendy; Lance Berman | Zendy; Bertram Pitt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

Author(s) -

Matthew R. Weir,

George L. Bakris,

David A. Bushinsky,

Martha Mayo,

Dahlia Garza,

Yuri Stasiv,

Janet Wittes,

Heidi ChristSchmidt,

Lance Berman,

Bertram Pitt

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1410853

Subject(s) - hyperkalemia , medicine , liter , kidney disease , clinical endpoint , confidence interval , aldosterone , placebo , potassium , urology , gastroenterology , randomized controlled trial , pathology , chemistry , alternative medicine , organic chemistry

Hyperkalemia increases the risk of death and limits the use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) in high-risk patients. We assessed the safety and efficacy of patiromer, a nonabsorbed potassium binder, in a multicenter, prospective trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research